Clinical trials: Hand-foot Syndrome
Palmar-Plantar Erythrodysesthesia, Palmar-Plantar Erythrodysesthesia Due to Cytotoxic Therapy
Efficacy and Safety of Moisturising Cream With or Without Vitamin E and Urea Cream in Palmar-plantar Erythrodysesthesia
This is a single-centre, phase II, three-arm, randomised controlled trial to evaluate the efficacy and safety of a cosmetic moisturising cream containing palm-oil-derived vitamin E concentrate or a similar moisturising cream…
- Trial name
- ECaPPE (NCT05939726)
- Testing
- Moisturising cream with vitamin E concentrate, Moisturising cream without vitamin E concentrate, Urea cream
- Where
- Malaysia
- Volunteers
- 145 people
- Sponsor
- Sarawak General Hospital
Breast Cancer, Palmar-plantar Erythrodysesthesia
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
RATIONALE: F511 cream may prevent or reduce palmar-plantar erythrodysesthesia in women receiving doxorubicin hydrochloride liposome for metastatic breast cancer.
- Trial name
- NCT00992706
- Testing
- antiperspirant cream F511, pegylated liposomal doxorubicin hydrochloride
- Where
- 15 sites in Switzerland
- Volunteers
- 91 people
- Sponsor
- Swiss Cancer Institute
the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine
A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer
The purpose of this study is the examination of Mapisal® versus urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot syndrome (HFS) in patients with gastrointestinal tumors or breast cancer, to assess the…
- Trial name
- PROCAPP (NCT01626781)
- Testing
- Mapisal, Urea hand-foot cream
- Where
- Germany
- Sponsor
- AIO-Studien-gGmbH
Ovarian Neoplasms
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.
- Trial name
- NCT00743431
- Testing
- Caelyx (Pegylated Lyposomal Doxorubicin)
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Gastric Cancer (GC)
Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)
Hand-foot syndrome (HFS) is a frequent adverse effect of capecitabine, presenting with redness, swelling, pain, and peeling of the skin on the palms and soles.
- Conditions
- Colorectal Cancer, Gastric Cancer (GC), Capecitabine, Hand Foot Syndrome
- Trial name
- DICLO-HFS (NCT07177560)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 151 people
- Sponsor
- Gazi University
Breast Cancer, Colorectal Cancer
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Colorectal Cancer, Palmar-plantar Erythrodysesthesia
- Trial name
- NCT00559858
- Testing
- pyridoxine hydrochloride, quality-of-life assessment
- Where
- 16 sites in United Kingdom
- Volunteers
- 270 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Hand and Foot Syndrome
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and…
- Trial name
- NCT00767689
- Testing
- Vitamin B 6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cook County Health
Hand Foot Syndrome
Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer
RATIONALE: Hand foot syndrome may be treated or reduced by soaking Traditional Chinese Medicine Formula LC09 in patients receiving capecitabine for colorectal and/or breast cancer.
- Trial name
- NCT02794493
- Testing
- Traditional Chinese Medicine Formula LC09
- Volunteers
- 156 people
- Sponsor
- China-Japan Friendship Hospital
Ovarian Neoplasm
DOXIL for Consolidation Therapy in Ovarian Cancer.
The primary objective for this study is to evaluate the development, frequency and severity of hand foot syndrome (HFS) in ovarian cancer subjects treated with Doxil®, as consolidation therapy, on an every two week schedule.
- Trial name
- NCT00248248
- Testing
- liposomal doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Southeastern Gynecologic Oncology
Cancer
The Preventive Effect of Chemotherapy-induced Hand-foot Syndrome
this study will use traditional Chinese medicine bath with no obvious side effects combined with case tracking management mode to form nursing measures to prevent hand foot syndrome.
- Trial name
- NCT06441513
- Testing
- Chinese traditional medicine nursing combined with case tracking management, Health Education
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University Third Hospital
Hand-Foot Syndrome
The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome
Chemotherapy or target therapy-induced hand-foot syndrome in cancer patients affects the quality of life. At present, there is no better treatment for this side effect of chemotherapy or target therapy.
- Trial name
- NCT05949307
- Testing
- acupuncture, laser acupuncture
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a 25%-50% of patients treated with several commonly used anti-cancer drugs including capecitabine and sunitinib.
- Trial name
- JADE (NCT01219023)
- Testing
- sildenafil citrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Breast Cancer, Colon Cancer
Eniluracil Hand Foot Syndrome
A pilot study of eniluracil containing ointment for prevention of hand foot syndrome (HRS) following capecitabine (Xeloda).
- Trial name
- NCT00827580
- Testing
- Eniluracil
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- West Virginia University
Hand and Foot Syndrome
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine
The aim of the study is to evaluate the efficacy of using combination of Urea-based cream (CARBAMIDE®) and topical diclofenac (VOLTAREN®) Emulgel 1% for improving the incidence of Hand-foot syndrome in histologically proven…
- Trial name
- NCT05641246
- Testing
- (CARBAMIDE®), (VOLTAREN®) Emulgel 1%
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- German University in Cairo
Hand-foot Syndrome
Acetylated Natural Nucleotides in Treating Hand-foot Syndrome
The clinical trial is planned to investigate the efficacy and safety of acetylated natural nucleotides in treating anti-cancer medications induced hand-foot syndrome (HFS).
- Trial name
- NCT04592731
- Testing
- Gel containing Acetylated Natural Nucleotides, Vehicle Gel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nan xu
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Palmar-plantar Erythrodysesthesia
Topical Antiperspirant for Hand-Foot Syndrome
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved…
- Trial name
- NCT00213993
- Testing
- antiperspirant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Hand-foot Syndrome
The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients
Comparative analysis of the severity of Hand-Foot-Syndrome (HFS) of palms treated with brimonidine tartrate gel or with standard care Urea 10% containing lotion in cancer patients receiving antineoplastic therapy to show a…
- Trial name
- BRIMOCAN (NCT03173365)
- Testing
- Brimonidine Tartrate
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Hand-Foot Syndrome
The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs
This study was a prospective, single-center randomized controlled trial. The subject of this study is to evaluate the effectiveness and safety of traditional Chinese medicine Liangxue Ointment in the treatment of hand-foot…
- Trial name
- NCT06583369
- Testing
- Liangxue ointment（Traditional Chinese Ointment）, Urea cream
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University Cancer Hospital & Institute